Page last updated: 2024-09-03

imatinib mesylate and Osteogenic Sarcoma

imatinib mesylate has been researched along with Osteogenic Sarcoma in 10 studies

Research

Studies (10)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	7 (70.00)	29.6817
2010's	3 (30.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Buchdunger, E; Germain, GS; Harwood, FC; Houghton, PJ; Schuetz, JD; Stewart, CF; Traxler, P	1
Blanchard, F; Brion, R; Charrier, C; Gobin, B; Heymann, D; Moriceau, G; Ory, B; Redini, F	1
Horiuchi, K; Kawakami, Y; Matsumoto, M; Morioka, H; Muto, A; Nakamura, M; Onishi, N; Saya, H; Shimizu, T; Sugihara, E; Toyama, Y; Ueki, A; Yaguchi, T; Yamaguchi, SI	1
Duesberg, P; Fabarius, A; Frank, O; Giehl, M; Haferlach, C; Hehlmann, R; Hochhaus, A; Krämer, A; Rebacz, B; Seifarth, W	1
Bakhshi, S; Das, P; Gupta, SD; Kalita, D; Radhakrishnan, S; Singh, S	1
Alves, MT; Burnier, MN; de Toledo, SR; Di Cesare, S; Garcia, RJ; Miiji, LN; Odashiro, AN; Petrilli, AS	1
Bar-Eli, M; Doucet, M; Fidler, IJ; Lev, DC; Lewis, V; McGary, EC; Mills, L; Weber, K	1
Aburatani, H; Hanyu, A; Imamura, T; Iwadate, M; Kondo, M; Matsuyama, S; Mishima, HK; Miyazawa, K; Miyazono, K; Saitoh, M; Shimizu, K	1
Adamson, PC; Bernstein, ML; Blaney, SM; Bond, M; Krailo, M; Pappo, A; Schultz, KR	1
Antonescu, CR; Chen, W; Gorlick, R; Healey, JH; Huvos, AG; Kim, HS; Kubo, T; Meyers, PA; Piperdi, S; Rosenblum, J; Sowers, R	1

Trials

1 trial(s) available for imatinib mesylate and Osteogenic Sarcoma

Article	Year
A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study. Pediatric blood & cancer, 2008, Volume: 50, Issue:2 Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial	2008

Article

Year

A phase II study of imatinib mesylate in children with refractory or relapsed solid tumors: a Children's Oncology Group study.

Pediatric blood & cancer, 2008, Volume: 50, Issue:2

Topics: Adolescent; Adult; Antineoplastic Agents; Benzamides; Bone Neoplasms; Carcinoma, Small Cell; Child; Child, Preschool; Female; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Male; Neoplasm Recurrence, Local; Neoplasms; Neuroblastoma; Osteosarcoma; Piperazines; Pyrimidines; Sarcoma, Ewing; Sarcoma, Synovial

2008

Other Studies

9 other study(ies) available for imatinib mesylate and Osteogenic Sarcoma

Article	Year
Imatinib mesylate is a potent inhibitor of the ABCG2 (BCRP) transporter and reverses resistance to topotecan and SN-38 in vitro. Cancer research, 2004, Apr-01, Volume: 64, Issue:7 Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Benzamides; Bone Neoplasms; Camptothecin; Cell Line, Tumor; Drug Resistance, Neoplasm; Enzyme Inhibitors; Humans; Imatinib Mesylate; Irinotecan; Neoplasm Proteins; Osteosarcoma; Piperazines; Pyrimidines; Topotecan	2004
Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PloS one, 2014, Volume: 9, Issue:3 Topics: Animals; Antineoplastic Agents; Benzamides; Caspases; Cell Cycle Checkpoints; Cell Death; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Disease Progression; Humans; Imatinib Mesylate; Immunocompetence; Male; Mice; Mice, Inbred C57BL; Mitosis; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-akt; Pyrimidines; Rats; Receptor, Platelet-Derived Growth Factor alpha; Signal Transduction; TOR Serine-Threonine Kinases	2014
Synergistic antiproliferative effect of imatinib and adriamycin in platelet-derived growth factor receptor-expressing osteosarcoma cells. Cancer science, 2015, Volume: 106, Issue:7 Topics: Animals; Antineoplastic Agents; Becaplermin; Benzamides; Cell Line, Tumor; Cell Proliferation; Doxorubicin; Drug Synergism; Female; Humans; Imatinib Mesylate; Mice, Inbred C57BL; Osteosarcoma; Piperazines; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor beta; Xenograft Model Antitumor Assays	2015
Centrosome aberrations and G1 phase arrest after in vitro and in vivo treatment with the SRC/ABL inhibitor dasatinib. Haematologica, 2008, Volume: 93, Issue:8 Topics: Animals; Antineoplastic Agents; Benzamides; Bone Marrow Cells; Cell Division; Cell Line, Tumor; Centrosome; CHO Cells; Cricetinae; Cricetulus; Fibroblasts; G1 Phase; Genes, abl; Genes, src; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Osteosarcoma; Piperazines; Pyrimidines; Skin Physiological Phenomena	2008
Presentation of childhood CML mimicking bone sarcoma. Pediatric blood & cancer, 2009, Volume: 52, Issue:7 Topics: Adolescent; Antineoplastic Agents; Benzamides; Blast Crisis; Bone Neoplasms; Diagnosis, Differential; Humans; Imatinib Mesylate; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Male; Osteosarcoma; Piperazines; Pyrimidines	2009
C-kit expression in human osteosarcoma and in vitro assays. International journal of clinical and experimental pathology, 2011, Volume: 4, Issue:8 Topics: Antineoplastic Agents; Benzamides; Biomarkers, Tumor; Bone Neoplasms; Cell Line, Tumor; Cell Movement; Cell Proliferation; Disease-Free Survival; Female; Humans; Imatinib Mesylate; Immunohistochemistry; In Vitro Techniques; Kaplan-Meier Estimate; Male; Osteosarcoma; Piperazines; Prognosis; Proto-Oncogene Proteins c-kit; Pyrimidines; Retrospective Studies	2011
Inhibition of platelet-derived growth factor-mediated proliferation of osteosarcoma cells by the novel tyrosine kinase inhibitor STI571. Clinical cancer research : an official journal of the American Association for Cancer Research, 2002, Volume: 8, Issue:11 Topics: Animals; Antineoplastic Agents; Benzamides; Blotting, Western; Bone Neoplasms; Cell Division; Cell Line, Transformed; Enzyme Inhibitors; Female; Humans; Imatinib Mesylate; In Situ Nick-End Labeling; Mice; Neoplasm Transplantation; Osteosarcoma; Paclitaxel; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Receptors, Platelet-Derived Growth Factor; Signal Transduction; Tibia; Time Factors; Tumor Cells, Cultured	2002
SB-431542 and Gleevec inhibit transforming growth factor-beta-induced proliferation of human osteosarcoma cells. Cancer research, 2003, Nov-15, Volume: 63, Issue:22 Topics: Activin Receptors, Type I; Activin Receptors, Type II; Animals; Antineoplastic Agents; Benzamides; Bone Neoplasms; Cell Division; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclins; Dioxoles; Drug Interactions; Gene Expression Regulation, Neoplastic; Humans; Imatinib Mesylate; Mice; NIH 3T3 Cells; Oligonucleotide Array Sequence Analysis; Osteosarcoma; Piperazines; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-myc; Pyrimidines; Receptor, Transforming Growth Factor-beta Type I; Receptors, Transforming Growth Factor beta; Signal Transduction; Transforming Growth Factor beta; Up-Regulation	2003
Platelet-derived growth factor receptor as a prognostic marker and a therapeutic target for imatinib mesylate therapy in osteosarcoma. Cancer, 2008, May-15, Volume: 112, Issue:10 Topics: Adolescent; Adult; Aged; Becaplermin; Benzamides; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Cell Survival; Child; Female; Humans; Imatinib Mesylate; Immunoenzyme Techniques; Immunoprecipitation; Male; Middle Aged; Mitogen-Activated Protein Kinases; Osteosarcoma; Phosphorylation; Piperazines; Platelet-Derived Growth Factor; Prognosis; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-sis; Pyrimidines; Receptor, Platelet-Derived Growth Factor alpha; Receptor, Platelet-Derived Growth Factor beta; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tumor Cells, Cultured	2008